Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Atomo Diagnostics Ltd

AT1.AX ✓ COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Advanced Medical Equipment & Technology ·

Australia Micro Cap Analyst: N/A

Last Close

$0.01

▲ +5.88%

Market Cap $11.51M · Vol 43.07K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$11.51M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

50.00

Momentum

Beta

1.69

vs Market

52W High

$0.03

63.92% below

52W Low

$0.01

9.92% above

Volume

43.07K

Avg 485.35K

P/B

1.99

Price-to-book

ROE

N/A

Return on equity

Free Float

58.33%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Atomo Diagnostics Ltd (AT1.AX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AT1.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-5.26%

+0.00%

-52.63%

YTD

-50.00%

-10.00%

-28.95%

-94.86%

Financials & Valuation

TTM · Annual

Total Revenue	$3.69M
Net Income	$-2,431,045.00
Revenue Growth (YoY)	+81.24%
Gross Margin	8.66%
Operating Margin	-87.62%
Net Profit Margin	-65.87%
ROE	N/A
ROA · ROIC	-34.96% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	2.64
P/B	1.99
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	902.43M

Technical Indicators

50-Day SMA	$0.01
200-Day SMA	$0.02
RSI (14)	50.00
Beta	1.69
52-Week High	$0.03
52-Week Low	$0.01

Volume Today	43.07K
Avg Daily Volume (30D)	485.35K
Relative Volume	0.09x
Volatility (10D)	84.80
Volatility (30D)	71.28
Free Float	58.33%

Analyst Consensus

N/A

Current Price $0.01

Mean Target N/A

52W Low$0.01 52W High$0.03

Current

Target

$0.01 $0.03

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG006Q6P2Y5

ISINAU0000080327

CountryAustralia

Sub-IndustryAdvanced Medical Equipment & Technology (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

TMO Thermo Fisher Scientific Inc +1.53% DHR Danaher Corporation +1.99% ISRG Intuitive Surgical, Inc. +0.33% BSX Boston Scientific Corp -0.82% EW Edwards Lifesciences Corporation -1.15%

Company Profile

Atomo Diagnostics Limited is an Australia-based medical device company. The Company supplies integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The Company’s patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has commercialized a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases, including COVID-19, HIV, viral vs bacterial differentiations as well as the early detection of pregnancy. Its products include Atomo HIV Self-Test, AtomoRapid Pascal and AtomoRapid Curie, among others. Its Atomo HIV Self-Test is an integrated, blood-based rapid diagnostic test (RDT) for HIV screening, which provides results in 15 minutes. The AtomoRapid Pascal platform offers improved performance and usability in point of care testing.